Inovalon Holdings Inc (INOV) was Downgraded by Piper Jaffray to ” Underweight”. Earlier the firm had a rating of “Neutral ” on the company shares. Piper Jaffray advised their investors in a research report released on Aug 4, 2016.
Many Wall Street Analysts have commented on Inovalon Holdings Inc. Inovalon Holdings Inc was Downgraded by Goldman to ” Neutral” on Aug 4, 2016.
On the company’s financial health, Inovalon Holdings Inc reported $0.14 EPS for the quarter, based on the information available during the earnings call on Aug 3, 2016. Analyst had a consensus estimate of $0.14. The company had revenue of $123.80 million for the quarter, compared to analysts expectations of $126.86 million. The company’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.18 EPS.
Inovalon Holdings Inc closed down -0.41 points or -2.15% at $18.65 with 3,98,650 shares getting traded on Tusday. Post opening the session at $19.04, the shares hit an intraday low of $18.095 and an intraday high of $19.17 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on May 10, 2016, Keith R Dunleavy (CEO) purchased 30,000 shares at $16.39 per share price. According to the SEC, on Mar 7, 2016, Robert A Wychulis (President) sold 33,003 shares at $18.17 per share price. On Dec 10, 2015, Daniel L Rizzo (Chief Innovation Officer) sold 24,000 shares at $20.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Inovalon Holdings Inc. is a technology company. The Company combines advanced cloud-based data analytics and data-driven intervention platforms to provide services for health plans hospitals physicians patients pharmaceutical companies and researchers. Through its datasets integration technologies predictive analytics and subject matter expertise the Company delivers platforms. Its analytics identify gaps in care quality data integrity and financial performance while providing clients with capabilities to resolve these gaps. The Company’s data analytics and intervention platforms consist of four primary components: data integration advanced analytics intervention platforms and business processing. This system manages the process of defining and configuring industry data feeds from its clients and partners including electronic health records laboratory pharmacy patient reported claims paper based medical records biometric and hospital data feeds.